NCT06550830View on ClinicalTrials.gov

Clinical Trial of PCV24 in Children Aged 2-17 Years

PHASE1RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

September 7, 2024

Primary Completion Date

July 20, 2025

Study Completion Date

September 14, 2025

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Sinovac PCV24 formulation 1

One dose of Sinovac PCV24 formulation 1(0.5mL)

BIOLOGICAL

Sinovac PCV24 formulation 2

One dose of Sinovac PCV24 formulation 2(0.5mL)

BIOLOGICAL

Prevenar13®

One dose of PCV13 manufactured by Pfizer

Trial Locations (1)

Unknown

RECRUITING

Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY